Targeted Oncology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1248210, encodeId=3b0c1248210db, content=这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17445694195, createdName=ms5000000784770068, createdTime=Fri Sep 09 21:37:54 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225317, encodeId=2b82122531e92, content=偏重的研究方向：综述 经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:57:02 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225318, encodeId=34b912253183a, content=偏重的研究方向：癌症;综述 经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:59:48 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561732, encodeId=d518561e323c, content=审稿速度:1.0 经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/06/65b1c2edc15a8f02bc91102330953561.jpg, createdBy=c7ab2448888, createdName=灬赫梦灬, createdTime=Sat Oct 06 00:00:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948565, encodeId=6ce5948565a1, content=请问有人投吗？为什么我提交文稿好几天了还是New Submission, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e85416830, createdName=ms5000000299297974, createdTime=Tue Mar 16 08:42:04 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205753, encodeId=f8001205e531b, content=要原始数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Fri Mar 25 07:00:05 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103163, encodeId=bef71103163a6, content=摘要中一定要加入研究目标么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103164, encodeId=3c9c11031642c, content=摘要撰写有什么套路？有没有模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567030, encodeId=32fd56e0300a, content=TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJnfAJcrGXTUIlWSAO09jv5HhQcnJr1v3E7z8MIVuicMJ3pCsHVmHy83812L0iahARrzS6RQFMgTTg/132, createdBy=f4a22469178, createdName=12433748m86(暂无昵称), createdTime=Wed Feb 20 23:52:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563457, encodeId=5e6356345eab, content=您好，我和您收到的一样，他们推荐的杂志都是sci收录的吗？136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span, beContent=136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er3UxGicC980EKc92ndV1cBYEGDyd0wziapVJ0KcPnu0S3QxngVtCgGIt9ehOm7sibVgcKOPIq7tsx6A/132, createdBy=2838104137, createdName=joemarton, createdTime=Wed Nov 21 00:00:00 CST 2018, time=2018-11-21, status=1, ipAttribution=)]

2022-09-09 ms5000000784770068

这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......

68 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1248210, encodeId=3b0c1248210db, content=这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17445694195, createdName=ms5000000784770068, createdTime=Fri Sep 09 21:37:54 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225317, encodeId=2b82122531e92, content=偏重的研究方向：综述 经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:57:02 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225318, encodeId=34b912253183a, content=偏重的研究方向：癌症;综述 经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:59:48 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561732, encodeId=d518561e323c, content=审稿速度:1.0 经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/06/65b1c2edc15a8f02bc91102330953561.jpg, createdBy=c7ab2448888, createdName=灬赫梦灬, createdTime=Sat Oct 06 00:00:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948565, encodeId=6ce5948565a1, content=请问有人投吗？为什么我提交文稿好几天了还是New Submission, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e85416830, createdName=ms5000000299297974, createdTime=Tue Mar 16 08:42:04 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205753, encodeId=f8001205e531b, content=要原始数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Fri Mar 25 07:00:05 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103163, encodeId=bef71103163a6, content=摘要中一定要加入研究目标么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103164, encodeId=3c9c11031642c, content=摘要撰写有什么套路？有没有模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567030, encodeId=32fd56e0300a, content=TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJnfAJcrGXTUIlWSAO09jv5HhQcnJr1v3E7z8MIVuicMJ3pCsHVmHy83812L0iahARrzS6RQFMgTTg/132, createdBy=f4a22469178, createdName=12433748m86(暂无昵称), createdTime=Wed Feb 20 23:52:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563457, encodeId=5e6356345eab, content=您好，我和您收到的一样，他们推荐的杂志都是sci收录的吗？136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span, beContent=136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er3UxGicC980EKc92ndV1cBYEGDyd0wziapVJ0KcPnu0S3QxngVtCgGIt9ehOm7sibVgcKOPIq7tsx6A/132, createdBy=2838104137, createdName=joemarton, createdTime=Wed Nov 21 00:00:00 CST 2018, time=2018-11-21, status=1, ipAttribution=)]

2022-06-08 ms6000000109847069

偏重的研究方向：综述
经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢

53 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1248210, encodeId=3b0c1248210db, content=这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17445694195, createdName=ms5000000784770068, createdTime=Fri Sep 09 21:37:54 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225317, encodeId=2b82122531e92, content=偏重的研究方向：综述 经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:57:02 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225318, encodeId=34b912253183a, content=偏重的研究方向：癌症;综述 经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:59:48 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561732, encodeId=d518561e323c, content=审稿速度:1.0 经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/06/65b1c2edc15a8f02bc91102330953561.jpg, createdBy=c7ab2448888, createdName=灬赫梦灬, createdTime=Sat Oct 06 00:00:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948565, encodeId=6ce5948565a1, content=请问有人投吗？为什么我提交文稿好几天了还是New Submission, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e85416830, createdName=ms5000000299297974, createdTime=Tue Mar 16 08:42:04 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205753, encodeId=f8001205e531b, content=要原始数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Fri Mar 25 07:00:05 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103163, encodeId=bef71103163a6, content=摘要中一定要加入研究目标么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103164, encodeId=3c9c11031642c, content=摘要撰写有什么套路？有没有模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567030, encodeId=32fd56e0300a, content=TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJnfAJcrGXTUIlWSAO09jv5HhQcnJr1v3E7z8MIVuicMJ3pCsHVmHy83812L0iahARrzS6RQFMgTTg/132, createdBy=f4a22469178, createdName=12433748m86(暂无昵称), createdTime=Wed Feb 20 23:52:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563457, encodeId=5e6356345eab, content=您好，我和您收到的一样，他们推荐的杂志都是sci收录的吗？136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span, beContent=136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er3UxGicC980EKc92ndV1cBYEGDyd0wziapVJ0KcPnu0S3QxngVtCgGIt9ehOm7sibVgcKOPIq7tsx6A/132, createdBy=2838104137, createdName=joemarton, createdTime=Wed Nov 21 00:00:00 CST 2018, time=2018-11-21, status=1, ipAttribution=)]

2022-06-08 ms6000000109847069

偏重的研究方向：癌症;综述
经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？

41 0

[GetPortalCommentsPageByObjectIdResponse(id=1248210, encodeId=3b0c1248210db, content=这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17445694195, createdName=ms5000000784770068, createdTime=Fri Sep 09 21:37:54 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225317, encodeId=2b82122531e92, content=偏重的研究方向：综述 经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:57:02 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225318, encodeId=34b912253183a, content=偏重的研究方向：癌症;综述 经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:59:48 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561732, encodeId=d518561e323c, content=审稿速度:1.0 经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/06/65b1c2edc15a8f02bc91102330953561.jpg, createdBy=c7ab2448888, createdName=灬赫梦灬, createdTime=Sat Oct 06 00:00:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948565, encodeId=6ce5948565a1, content=请问有人投吗？为什么我提交文稿好几天了还是New Submission, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e85416830, createdName=ms5000000299297974, createdTime=Tue Mar 16 08:42:04 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205753, encodeId=f8001205e531b, content=要原始数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Fri Mar 25 07:00:05 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103163, encodeId=bef71103163a6, content=摘要中一定要加入研究目标么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103164, encodeId=3c9c11031642c, content=摘要撰写有什么套路？有没有模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567030, encodeId=32fd56e0300a, content=TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJnfAJcrGXTUIlWSAO09jv5HhQcnJr1v3E7z8MIVuicMJ3pCsHVmHy83812L0iahARrzS6RQFMgTTg/132, createdBy=f4a22469178, createdName=12433748m86(暂无昵称), createdTime=Wed Feb 20 23:52:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563457, encodeId=5e6356345eab, content=您好，我和您收到的一样，他们推荐的杂志都是sci收录的吗？136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span, beContent=136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er3UxGicC980EKc92ndV1cBYEGDyd0wziapVJ0KcPnu0S3QxngVtCgGIt9ehOm7sibVgcKOPIq7tsx6A/132, createdBy=2838104137, createdName=joemarton, createdTime=Wed Nov 21 00:00:00 CST 2018, time=2018-11-21, status=1, ipAttribution=)]

2018-10-06 灬赫梦灬

审稿速度:1.0
经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）

268 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1248210, encodeId=3b0c1248210db, content=这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17445694195, createdName=ms5000000784770068, createdTime=Fri Sep 09 21:37:54 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225317, encodeId=2b82122531e92, content=偏重的研究方向：综述 经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:57:02 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225318, encodeId=34b912253183a, content=偏重的研究方向：癌症;综述 经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:59:48 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561732, encodeId=d518561e323c, content=审稿速度:1.0 经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/06/65b1c2edc15a8f02bc91102330953561.jpg, createdBy=c7ab2448888, createdName=灬赫梦灬, createdTime=Sat Oct 06 00:00:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948565, encodeId=6ce5948565a1, content=请问有人投吗？为什么我提交文稿好几天了还是New Submission, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e85416830, createdName=ms5000000299297974, createdTime=Tue Mar 16 08:42:04 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205753, encodeId=f8001205e531b, content=要原始数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Fri Mar 25 07:00:05 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103163, encodeId=bef71103163a6, content=摘要中一定要加入研究目标么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103164, encodeId=3c9c11031642c, content=摘要撰写有什么套路？有没有模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567030, encodeId=32fd56e0300a, content=TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJnfAJcrGXTUIlWSAO09jv5HhQcnJr1v3E7z8MIVuicMJ3pCsHVmHy83812L0iahARrzS6RQFMgTTg/132, createdBy=f4a22469178, createdName=12433748m86(暂无昵称), createdTime=Wed Feb 20 23:52:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563457, encodeId=5e6356345eab, content=您好，我和您收到的一样，他们推荐的杂志都是sci收录的吗？136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span, beContent=136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er3UxGicC980EKc92ndV1cBYEGDyd0wziapVJ0KcPnu0S3QxngVtCgGIt9ehOm7sibVgcKOPIq7tsx6A/132, createdBy=2838104137, createdName=joemarton, createdTime=Wed Nov 21 00:00:00 CST 2018, time=2018-11-21, status=1, ipAttribution=)]

2021-03-16 ms5000000299297974

请问有人投吗？为什么我提交文稿好几天了还是New Submission

82 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=1248210, encodeId=3b0c1248210db, content=这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17445694195, createdName=ms5000000784770068, createdTime=Fri Sep 09 21:37:54 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225317, encodeId=2b82122531e92, content=偏重的研究方向：综述 经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:57:02 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225318, encodeId=34b912253183a, content=偏重的研究方向：癌症;综述 经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:59:48 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561732, encodeId=d518561e323c, content=审稿速度:1.0 经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/06/65b1c2edc15a8f02bc91102330953561.jpg, createdBy=c7ab2448888, createdName=灬赫梦灬, createdTime=Sat Oct 06 00:00:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948565, encodeId=6ce5948565a1, content=请问有人投吗？为什么我提交文稿好几天了还是New Submission, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e85416830, createdName=ms5000000299297974, createdTime=Tue Mar 16 08:42:04 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205753, encodeId=f8001205e531b, content=要原始数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Fri Mar 25 07:00:05 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103163, encodeId=bef71103163a6, content=摘要中一定要加入研究目标么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103164, encodeId=3c9c11031642c, content=摘要撰写有什么套路？有没有模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567030, encodeId=32fd56e0300a, content=TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJnfAJcrGXTUIlWSAO09jv5HhQcnJr1v3E7z8MIVuicMJ3pCsHVmHy83812L0iahARrzS6RQFMgTTg/132, createdBy=f4a22469178, createdName=12433748m86(暂无昵称), createdTime=Wed Feb 20 23:52:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563457, encodeId=5e6356345eab, content=您好，我和您收到的一样，他们推荐的杂志都是sci收录的吗？136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span, beContent=136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er3UxGicC980EKc92ndV1cBYEGDyd0wziapVJ0KcPnu0S3QxngVtCgGIt9ehOm7sibVgcKOPIq7tsx6A/132, createdBy=2838104137, createdName=joemarton, createdTime=Wed Nov 21 00:00:00 CST 2018, time=2018-11-21, status=1, ipAttribution=)]

2022-03-25 12133f96m16(暂无昵称)

要原始数据？

52 0

[GetPortalCommentsPageByObjectIdResponse(id=1248210, encodeId=3b0c1248210db, content=这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17445694195, createdName=ms5000000784770068, createdTime=Fri Sep 09 21:37:54 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225317, encodeId=2b82122531e92, content=偏重的研究方向：综述 经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:57:02 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225318, encodeId=34b912253183a, content=偏重的研究方向：癌症;综述 经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:59:48 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561732, encodeId=d518561e323c, content=审稿速度:1.0 经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/06/65b1c2edc15a8f02bc91102330953561.jpg, createdBy=c7ab2448888, createdName=灬赫梦灬, createdTime=Sat Oct 06 00:00:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948565, encodeId=6ce5948565a1, content=请问有人投吗？为什么我提交文稿好几天了还是New Submission, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e85416830, createdName=ms5000000299297974, createdTime=Tue Mar 16 08:42:04 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205753, encodeId=f8001205e531b, content=要原始数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Fri Mar 25 07:00:05 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103163, encodeId=bef71103163a6, content=摘要中一定要加入研究目标么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103164, encodeId=3c9c11031642c, content=摘要撰写有什么套路？有没有模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567030, encodeId=32fd56e0300a, content=TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJnfAJcrGXTUIlWSAO09jv5HhQcnJr1v3E7z8MIVuicMJ3pCsHVmHy83812L0iahARrzS6RQFMgTTg/132, createdBy=f4a22469178, createdName=12433748m86(暂无昵称), createdTime=Wed Feb 20 23:52:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563457, encodeId=5e6356345eab, content=您好，我和您收到的一样，他们推荐的杂志都是sci收录的吗？136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span, beContent=136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er3UxGicC980EKc92ndV1cBYEGDyd0wziapVJ0KcPnu0S3QxngVtCgGIt9ehOm7sibVgcKOPIq7tsx6A/132, createdBy=2838104137, createdName=joemarton, createdTime=Wed Nov 21 00:00:00 CST 2018, time=2018-11-21, status=1, ipAttribution=)]

2021-12-28 Mia

摘要中一定要加入研究目标么？

53 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1248210, encodeId=3b0c1248210db, content=这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17445694195, createdName=ms5000000784770068, createdTime=Fri Sep 09 21:37:54 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225317, encodeId=2b82122531e92, content=偏重的研究方向：综述 经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:57:02 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225318, encodeId=34b912253183a, content=偏重的研究方向：癌症;综述 经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:59:48 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561732, encodeId=d518561e323c, content=审稿速度:1.0 经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/06/65b1c2edc15a8f02bc91102330953561.jpg, createdBy=c7ab2448888, createdName=灬赫梦灬, createdTime=Sat Oct 06 00:00:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948565, encodeId=6ce5948565a1, content=请问有人投吗？为什么我提交文稿好几天了还是New Submission, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e85416830, createdName=ms5000000299297974, createdTime=Tue Mar 16 08:42:04 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205753, encodeId=f8001205e531b, content=要原始数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Fri Mar 25 07:00:05 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103163, encodeId=bef71103163a6, content=摘要中一定要加入研究目标么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103164, encodeId=3c9c11031642c, content=摘要撰写有什么套路？有没有模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567030, encodeId=32fd56e0300a, content=TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJnfAJcrGXTUIlWSAO09jv5HhQcnJr1v3E7z8MIVuicMJ3pCsHVmHy83812L0iahARrzS6RQFMgTTg/132, createdBy=f4a22469178, createdName=12433748m86(暂无昵称), createdTime=Wed Feb 20 23:52:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563457, encodeId=5e6356345eab, content=您好，我和您收到的一样，他们推荐的杂志都是sci收录的吗？136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span, beContent=136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er3UxGicC980EKc92ndV1cBYEGDyd0wziapVJ0KcPnu0S3QxngVtCgGIt9ehOm7sibVgcKOPIq7tsx6A/132, createdBy=2838104137, createdName=joemarton, createdTime=Wed Nov 21 00:00:00 CST 2018, time=2018-11-21, status=1, ipAttribution=)]

2021-12-27 桑晒麦拉

摘要撰写有什么套路？有没有模板？

53 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1248210, encodeId=3b0c1248210db, content=这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17445694195, createdName=ms5000000784770068, createdTime=Fri Sep 09 21:37:54 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225317, encodeId=2b82122531e92, content=偏重的研究方向：综述 经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:57:02 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225318, encodeId=34b912253183a, content=偏重的研究方向：癌症;综述 经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:59:48 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561732, encodeId=d518561e323c, content=审稿速度:1.0 经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/06/65b1c2edc15a8f02bc91102330953561.jpg, createdBy=c7ab2448888, createdName=灬赫梦灬, createdTime=Sat Oct 06 00:00:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948565, encodeId=6ce5948565a1, content=请问有人投吗？为什么我提交文稿好几天了还是New Submission, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e85416830, createdName=ms5000000299297974, createdTime=Tue Mar 16 08:42:04 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205753, encodeId=f8001205e531b, content=要原始数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Fri Mar 25 07:00:05 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103163, encodeId=bef71103163a6, content=摘要中一定要加入研究目标么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103164, encodeId=3c9c11031642c, content=摘要撰写有什么套路？有没有模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567030, encodeId=32fd56e0300a, content=TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJnfAJcrGXTUIlWSAO09jv5HhQcnJr1v3E7z8MIVuicMJ3pCsHVmHy83812L0iahARrzS6RQFMgTTg/132, createdBy=f4a22469178, createdName=12433748m86(暂无昵称), createdTime=Wed Feb 20 23:52:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563457, encodeId=5e6356345eab, content=您好，我和您收到的一样，他们推荐的杂志都是sci收录的吗？136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span, beContent=136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er3UxGicC980EKc92ndV1cBYEGDyd0wziapVJ0KcPnu0S3QxngVtCgGIt9ehOm7sibVgcKOPIq7tsx6A/132, createdBy=2838104137, createdName=joemarton, createdTime=Wed Nov 21 00:00:00 CST 2018, time=2018-11-21, status=1, ipAttribution=)]

2019-02-20 12433748m86(暂无昵称)

TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？

195 0

[GetPortalCommentsPageByObjectIdResponse(id=1248210, encodeId=3b0c1248210db, content=这个杂志的要求不能理解，要求提供被拒稿的审稿意见并作出说明，头都大了，提供被拒的审稿意见不就会被再次拒稿吗......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17445694195, createdName=ms5000000784770068, createdTime=Fri Sep 09 21:37:54 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225317, encodeId=2b82122531e92, content=偏重的研究方向：综述 经验分享：投稿后4天了，一直是new submission。有人一样的情况吗？要不要催呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:57:02 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225318, encodeId=34b912253183a, content=偏重的研究方向：癌症;综述 经验分享：投稿4天了，一直是new submission，不知道什么情况，要催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1466158912, createdName=ms6000000109847069, createdTime=Wed Jun 08 23:59:48 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561732, encodeId=d518561e323c, content=审稿速度:1.0 经验分享：投了一篇文章，审稿非常效率，3天后就回复了。说是文章不在这个期刊的范围内 (原文："Targeted Oncology focuses on the development and use of molecularly targeted agents in oncology. Your current submission is therefore outside the scope of the journal.")，推荐我使用"The Springer Transfer Desk service"推荐给我合适的期刊，已同意，等待回复期刊列表中。我会持续更新最新动态，给以后大家的投稿提供经验吧，勿喷谢谢。（＾＿＾）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/06/65b1c2edc15a8f02bc91102330953561.jpg, createdBy=c7ab2448888, createdName=灬赫梦灬, createdTime=Sat Oct 06 00:00:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948565, encodeId=6ce5948565a1, content=请问有人投吗？为什么我提交文稿好几天了还是New Submission, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e85416830, createdName=ms5000000299297974, createdTime=Tue Mar 16 08:42:04 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205753, encodeId=f8001205e531b, content=要原始数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Fri Mar 25 07:00:05 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103163, encodeId=bef71103163a6, content=摘要中一定要加入研究目标么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103164, encodeId=3c9c11031642c, content=摘要撰写有什么套路？有没有模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567030, encodeId=32fd56e0300a, content=TARGETED ONCOLOGY 利益声明表的通讯作者那一栏是填是否，还是填通讯作者名字？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJnfAJcrGXTUIlWSAO09jv5HhQcnJr1v3E7z8MIVuicMJ3pCsHVmHy83812L0iahARrzS6RQFMgTTg/132, createdBy=f4a22469178, createdName=12433748m86(暂无昵称), createdTime=Wed Feb 20 23:52:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563457, encodeId=5e6356345eab, content=您好，我和您收到的一样，他们推荐的杂志都是sci收录的吗？136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span, beContent=136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er3UxGicC980EKc92ndV1cBYEGDyd0wziapVJ0KcPnu0S3QxngVtCgGIt9ehOm7sibVgcKOPIq7tsx6A/132, createdBy=2838104137, createdName=joemarton, createdTime=Wed Nov 21 00:00:00 CST 2018, time=2018-11-21, status=1, ipAttribution=)]

2018-11-21 joemarton

您好，我和您收到的一样，他们推荐的杂志都是sci收录的吗？136****8038(暂无匿称) 2018-11-09 22:16:00 发表:
请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span

136****8038(暂无匿称) 2018-11-09 22:16:00 发表: 请问需要审稿费吗spanclassquote灬赫梦灬20181006发表br审稿时间约1个月投了一篇文章审稿非常效率3天后就回复了说是文章不在这个期刊的范围内原文TargetedOncologyfocusesonthedevelopmentanduseofmolecularlytargetedagentsinoncologyYourcurrentsubmissionisthereforeoutsidethescopeofthejournal推荐我使用TheSpringerTransferDeskservice推荐给我合适的期刊已同意等待回复期刊列表中我会持续更新最新动态给以后大家的投稿提供经验吧勿喷谢谢span

200 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务